SunTrust Downgrades Intra-Cellular Therapies (ITCI) to Neutral
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 25
Join SI Premium – FREE
SunTrust Robinson Humphrey downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Buy to Neutral with a price target of $15.00 (from $60.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $42.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stephens Downgrades Bio-Techne Corp. (TECH) to Equal Weight
- Coforge Ltd (COFORGE:IN) PT Raised to INR1,235 at Citi
- LTM Ltd (LTM:IN) PT Lowered to INR3,455 at Citi
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
The Children's Investment Fund (TCI), SunTrust Robinson HumphreySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
